Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Hicks

Showing results (111-120 of 132) with videos related to

Pageof 14
Sort By:
Breast Cancer Research : BCR|March 25, 2009
TLE3 as a candidate biomarker of response to taxane therapySwati A Kulkarni, David G Hicks, Nancy L Watroba, et al.
Breast Cancer : Basic and Clinical Research|January 20, 2012
Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patientsJi-Ping Qi, You-Lin Yang, Hong Zhu, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|February 19, 2014
A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissueVeronique M Neumeister, Fabio Parisi, Allison M England, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancerBrian Z Ring, Robert S Seitz, Rod Beck, et al.
The Breast Journal|February 27, 2007
The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical studySarah M Short, Brian J Yoder, Shannon M Tarr, et al.
The American Journal of Surgical Pathology|August 26, 2006
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFRDavid G Hicks, Sarah M Short, Nichole L Prescott, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 1, 2007
A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibilityWilliam C Powell, David G Hicks, Nichole Prescott, et al.
Cancer Research|January 13, 2011
Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progressionSanjib Banerjee, Chuen-Fu L Lin, Kristin A Skinner, et al.
BMC Cancer|March 24, 2010
The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrenceDavid G Hicks, Bagi R Janarthanan, Ramya Vardarajan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCatherine Van Poznak, Mark R Somerfield, Robert C Bast, et al.
Pageof 14

Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
Breast Cancer Research : BCR|March 25, 2009
TLE3 as a candidate biomarker of response to taxane therapySwati A Kulkarni, David G Hicks, Nancy L Watroba, et al.
Breast Cancer : Basic and Clinical Research|January 20, 2012
Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patientsJi-Ping Qi, You-Lin Yang, Hong Zhu, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|February 19, 2014
A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissueVeronique M Neumeister, Fabio Parisi, Allison M England, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancerBrian Z Ring, Robert S Seitz, Rod Beck, et al.
The Breast Journal|February 27, 2007
The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical studySarah M Short, Brian J Yoder, Shannon M Tarr, et al.
The American Journal of Surgical Pathology|August 26, 2006
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFRDavid G Hicks, Sarah M Short, Nichole L Prescott, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 1, 2007
A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibilityWilliam C Powell, David G Hicks, Nichole Prescott, et al.
Cancer Research|January 13, 2011
Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progressionSanjib Banerjee, Chuen-Fu L Lin, Kristin A Skinner, et al.
BMC Cancer|March 24, 2010
The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrenceDavid G Hicks, Bagi R Janarthanan, Ramya Vardarajan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCatherine Van Poznak, Mark R Somerfield, Robert C Bast, et al.
Pageof 14